|
1
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Döhner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marchand T and Pinho S: Leukemic stem
cells: From leukemic niche biology to treatment opportunities.
Front Immunol. 12:7751282021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Méndez-Ferrer S, Bonnet D, Steensma DP,
Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M and Krause DS:
Bone marrow niches in haematological malignancies. Nat Rev Cancer.
20:285–298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Virgilio F, Sarti AC, Falzoni S, De
Marchi E and Adinolfi E: Extracellular ATP and P2 purinergic
signalling in the tumour microenvironment. Nat Rev Cancer.
18:601–618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lara R, Adinolfi E, Harwood CA, Philpott
M, Barden JA, Di Virgilio F and McNulty S: P2X7 in cancer: From
molecular mechanisms to therapeutics. Front Pharmacol. 11:7932020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He X, Zhang Y, Xu Y, Xie L, Yu Z and Zheng
J: Function of the P2X7 receptor in hematopoiesis and
leukemogenesis. Exp Hematol. 104:40–47. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Acuña-Castillo C, Escobar A, García-Gómez
M, Bachelet VC, Huidobro-Toro JP, Sauma D and Barrera-Avalos C:
P2X7 receptor in dendritic cells and macrophages: Implications in
antigen presentation and T lymphocyte activation. Int J Mol Sci.
25:24952024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Torre-Minguela C, Barberà-Cremades M,
Gómez AI, Martín-Sánchez F and Pelegrín P: Macrophage activation
and polarization modify P2X7 receptor secretome influencing the
inflammatory process. Sci Rep. 6:225862016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Story ME, Hao X, Sumpter TL and
Mathers AR: P2X7 receptor expression and signaling on dendritic
cells and CD4+ T cells is not required but can enhance Th17
differentiation. FronT cell Dev Biol. 10:6876592022. View Article : Google Scholar
|
|
11
|
Rivas-Yáñez E, Barrera-Avalos C,
Parra-Tello B, Briceño P, Rosemblatt MV, Saavedra-Almarza J,
Rosemblatt M, Acuña-Castillo C, Bono MR and Sauma D: P2X7 receptor
at the crossroads of T cell fate. Int J Mol Sci. 21:49372020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He X, Wan J, Yang X, Zhang X, Huang D, Li
X, Zou Y, Chen C, Yu Z, Xie L, et al: Bone marrow niche ATP levels
determine leukemia-initiating cell activity via P2X7 in leukemic
models. J Clin Invest. 131:e1402422021. View Article : Google Scholar
|
|
13
|
Feng W, Yang X, Wang L, Wang R, Yang F,
Wang H, Liu X, Ren Q, Zhang Y, Zhu X and Zheng G: P2X7 promotes the
progression of MLL-AF9 induced acute myeloid leukemia by
upregulation of Pbx3. Haematologica. 106:1278–1289. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gilbert SM, Gidley Baird A, Glazer S,
Barden JA, Glazer A, Teh LC and King J: A phase I clinical trial
demonstrates that nfP2X7-targeted antibodies provide a novel, safe
and tolerable topical therapy for basal cell carcinoma. Br J
Dermatol. 177:117–124. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roger S and Pelegrin P: P2X7 receptor
antagonism in the treatment of cancers. Expert Opin Investig Drugs.
20:875–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Buell GN, Talabot F, Gos A, Lorenz J, Lai
E, Morris MA and Antonarakis SE: Gene structure and chromosomal
localization of the human P2X7 receptor. Recept Channels.
5:347–354. 1998.PubMed/NCBI
|
|
17
|
Jiang LH, Caseley EA, Muench SP and Roger
S: Structural basis for the functional properties of the P2X7
receptor for extracellular ATP. Purinergic Signal. 17:331–344.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saul A, Hausmann R, Kless A and Nicke A:
Heteromeric assembly of P2X subunits. FronT cell Neurosci.
7:2502013. View Article : Google Scholar
|
|
19
|
Boumechache M, Masin M, Edwardson JM,
Górecki DC and Murrell-Lagnado R: Analysis of assembly and
trafficking of native P2X4 and P2X7 receptor complexes in rodent
immune cells. J Biol Chem. 284:13446–13454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheng D and Hattori M: Recent progress in
the structural biology of P2X receptors. Proteins. 90:1779–1785.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hattori M and Gouaux E: Molecular
mechanism of ATP binding and ion channel activation in P2X
receptors. Nature. 485:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang LH, Baldwin JM, Roger S and Baldwin
SA: Insights into the molecular mechanisms underlying mammalian
P2X7 receptor functions and contributions in diseases, revealed by
structural modeling and single nucleotide polymorphisms. Front
Pharmacol. 4:552013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Di Virgilio F, Schmalzing G and Markwardt
F: The elusive P2X7 macropore. Trends Cell Biol. 28:392–404. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cevoli F, Arnould B, Peralta FA and
Grutter T: Untangling macropore formation and current facilitation
in P2X7. Int J Mol Sci. 24:108962023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang WJ, Hu CG, Zhu ZM and Luo HL: Effect
of P2X7 receptor on tumorigenesis and its pharmacological
properties. Biomed Pharmacother. 125:1098442020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang GP, Liao JX, Liu YY, Zhu FQ, Huang
HJ and Zhang WJ: Ion channel P2X7 receptor in the progression of
cancer. Front Oncol. 13:12977752023. View Article : Google Scholar
|
|
27
|
Di Virgilio F, Vultaggio-Poma V and Sarti
AC: P2X receptors in cancer growth and progression. Biochem
Pharmacol. 187:1143502021. View Article : Google Scholar
|
|
28
|
Kopp R, Krautloher A, Ramírez-Fernández A
and Nicke A: P2X7 interactions and signaling-making head or tail of
it. Front Mol Neurosci. 12:1832019. View Article : Google Scholar
|
|
29
|
Harkat M, Peverini L, Cerdan AH, Dunning
K, Beudez J, Martz A, Calimet N, Specht A, Cecchini M, Chataigneau
T and Grutter T: On the permeation of large organic cations through
the pore of ATP-gated P2X receptors. Proc Natl Acad Sci USA.
114:E3786–E3795. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Di Virgilio F, Giuliani AL, Vultaggio-Poma
V, Falzoni S and Sarti AC: Non-nucleotide agonists triggering P2X7
receptor activation and pore formation. Front Pharmacol. 9:392018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martínez-Cuesta MÁ, Blanch-Ruiz MA,
Ortega-Luna R, Sánchez-López A and Álvarez Á: Structural and
functional basis for understanding the biological significance of
P2X7 receptor. Int J Mol Sci. 21:84542020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ziberi S, Zuccarini M, Carluccio M,
Giuliani P, Ricci-Vitiani L, Pallini R, Caciagli F, Di Iorio P and
Ciccarelli R: Upregulation of Epithelial-to-Mesenchymal transition
markers and P2X7 receptors is associated to increased invasiveness
caused by P2X7 receptor stimulation in human glioblastoma stem
cells. Cells. 9:852019. View Article : Google Scholar
|
|
33
|
Ulrich H, Ratajczak MZ, Schneider G,
Adinolfi E, Orioli E, Ferrazoli EG, Glaser T, Corrêa-Velloso J,
Martins PCM, Coutinho F, et al: Kinin and purine signaling
contributes to neuroblastoma metastasis. Front Pharmacol.
9:5002018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Giuliani AL, Colognesi D, Ricco T, Roncato
C, Capece M, Amoroso F, Wang QG, De Marchi E, Gartland A, Di
Virgilio F and Adinolfi E: Trophic activity of human P2X7 receptor
isoforms a and B in osteosarcoma. PLoS One. 9:e1072242014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Benzaquen J, Heeke S, Janho dit Hreich S,
Douguet L, Marquette CH, Hofman P and Vouret-Craviari V:
Alternative splicing of P2RX7 pre-messenger RNA in health and
diseases: Myth or reality? Biomed J. 42:141–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Salis SKF, Li L, Chen Z, Lam KW,
Skarratt KK, Balle T and Fuller SJ: Alternatively spliced isoforms
of the P2X7 receptor: Structure, function and disease associations.
Int J Mol Sci. 23:81742022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pegoraro A, Orioli E, De Marchi E,
Salvestrini V, Milani A, Di Virgilio F, Curti A and Adinolfi E:
Differential sensitivity of acute myeloid leukemia cells to
daunorubicin depends on P2X7A versus P2X7B receptor expression.
Cell Death Dis. 11:8762020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gilbert S, Oliphant CJ, Hassan S, Peille
AL, Bronsert P, Falzoni S, Di Virgilio F, McNulty S and Lara R: ATP
in the tumour microenvironment drives expression of
nfP2X7, a key mediator of cancer cell survival.
Oncogene. 38:194–208. 2019. View Article : Google Scholar :
|
|
39
|
Pegoraro A, De Marchi E and Adinolfi E:
P2X7 variants in oncogenesis. Cells. 10:1892021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Magni L, Yu H, Christensen NM, Poulsen MH,
Frueh A, Deshar G, Johansen AZ, Johansen JS, Pless SA, Jørgensen NR
and Novak I: Human P2X7 receptor variants Gly150Arg and Arg276His
polymorphisms have differential effects on risk association and
cellular functions in pancreatic cancer. Cancer Cell Int.
24:1482024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shemon AN, Sluyter R, Fernando SL, Clarke
AL, Dao-Ung LP, Skarratt KK, Saunders BM, Tan KS, Gu BJ, Fuller SJ,
et al: A Thr357 to Ser polymorphism in homozygous and compound
heterozygous subjects causes absent or reduced P2X7 function and
impairs ATP-induced mycobacterial killing by macrophages. J Biol
Chem. 281:2079–2086. 2006. View Article : Google Scholar
|
|
42
|
Schäfer W, Stähler T, Pinto Espinoza C,
Danquah W, Knop JH, Rissiek B, Haag F and Koch-Nolte F: Origin,
distribution, and function of three frequent coding polymorphisms
in the gene for the human P2X7 ion channel. Front Pharmacol.
13:10331352022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lecciso M, Ocadlikova D, Sangaletti S,
Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P,
Jandus C, Bontadini A, et al: ATP release from chemotherapy-treated
dying leukemia cells elicits an immune suppressive effect by
increasing regulatory T cells and tolerogenic dendritic cells.
Front Immunol. 8:19182017. View Article : Google Scholar
|
|
44
|
Thomas LM and Salter RD: Activation of
macrophages by P2X7-induced microvesicles from myeloid cells is
mediated by phospholipids and is partially dependent on TLR4. J
Immunol. 185:3740–3749. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen DW, Fan JM, Schrey JM, Mitchell DV,
Jung SK, Hurwitz SN, Perez EB, Muraro MJ, Carroll M, Taylor DM and
Kurre P: Inflammatory recruitment of healthy hematopoietic stem and
progenitor cells in the acute myeloid leukemia niche. Leukemia.
38:741–750. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Matthes T: Phenotypic analysis of
hematopoietic stem and progenitor cell populations in acute myeloid
leukemia based on spectral flow cytometry, a 20-color panel, and
unsupervised learning algorithms. Int J Mol Sci. 25:28472024.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bao J, Freund O, Sund L and Du W: Inside
the battle against acute myeloid leukemia: Biology, breakthroughs,
and hope. Cells. 15:3382026. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lenkiewicz AM, Adamiak M, Thapa A, Bujko
K, Pedziwiatr D, Abdel-Latif AK, Kucia M, Ratajczak J and Ratajczak
MZ: The Nlrp3 inflammasome orchestrates mobilization of bone
marrow-residing stem cells into peripheral blood. Stem Cell Rev
Rep. 15:391–403. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng W, Yang F, Wang R, Yang X, Wang L,
Chen C, Liao J, Lin Y, Ren Q and Zheng G: High level P2X7-mediated
signaling impairs function of hematopoietic stem/progenitor cells.
Stem Cell Rev Rep. 12:305–314. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tung LT, Wang H, Belle JI, Petrov JC,
Langlais D and Nijnik A: p53-dependent induction of P2X7 on
hematopoietic stem and progenitor cells regulates hematopoietic
response to genotoxic stress. Cell Death Dis. 12:9232021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gu BJ, Zhang WY, Bendall LJ, Chessell IP,
Buell GN and Wiley JS: Expression of P2X(7) purinoceptors on human
lymphocytes and monocytes: Evidence for nonfunctional P2X(7)
receptors. Am J Physiol Cell Physiol. 279:C1189–C1197. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Scherr BF, Reiner MF, Baumann F, Höhne K,
Müller T, Ayata K, Müller-Quernheim J, Idzko M and Zissel G:
Prevention of M2 polarization and temporal limitation of
differentiation in monocytes by extracellular ATP. BMC Immunol.
24:112023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Virgilio FD, Ben DD, Sarti AC, Giuliani AL
and Falzoni S: The P2X7 receptor in infection and inflammation.
Immunity. 47:15–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pelegrin P and Surprenant A: Dynamics of
macrophage polarization reveal new mechanism to inhibit IL-1beta
release through pyrophosphates. EMBO J. 28:2114–2127. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lopez-Castejón G, Baroja-Mazo A and
Pelegrín P: Novel macrophage polarization model: From gene
expression to identification of new anti-inflammatory molecules.
Cell Mol Life Sci CMLS. 68:3095–3107. 2011. View Article : Google Scholar
|
|
56
|
Chen SY, Feng WL, Yang X, Liao JF, Wang
LN, Lin YM, Ren Q and Zheng GG: Expression of P2X family receptors
in peritoneal macrophages of mouse with acute T lymphoblastic
leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:623–628. 2014.In
Chinese. PubMed/NCBI
|
|
57
|
Pelegrin P: P2X7 receptor and the NLRP3
inflammasome: Partners in crime. Biochem Pharmacol. 187:1143852021.
View Article : Google Scholar
|
|
58
|
Miari KE, Guzman ML, Wheadon H and
Williams MTS: Macrophages in acute myeloid leukaemia: Significant
players in therapy resistance and patient outcomes. FronT cell Dev
Biol. 9:6928002021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Weinhäuser I, Pereira-Martins DA, Almeida
LY, Hilberink JR, Silveira DRA, Quek L, Ortiz C, Araujo CL, Bianco
TM, Lucena-Araujo A, et al: M2 macrophages drive leukemic
transformation by imposing resistance to phagocytosis and improving
mitochondrial metabolism. Sci Adv. 9:eadf85222023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen ZG, Yang H, Yang C, Xie YT, Li CM,
Xiao T, Wu JH, Gao MY, Wang CC, Zhao YL, et al: Macrophage
polarization in hematologic cancers: Mechanisms and therapeutic
strategies. Blood Res. 61:82026. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yu Y, Feng S, Wei S, Zhong Y, Yi G, Chen
H, Liang L, Chen H and Lu X: Extracellular ATP activates
P2X7R-NF-κB (p65) pathway to promote the maturation of bone
marrow-derived dendritic cells of mice. Cytokine. 119:175–181.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li R, Wang J, Li R, Zhu F, Xu W, Zha G, He
G, Cao H, Wang Y and Yang J: ATP/P2X7-NLRP3 axis of dendritic cells
participates in the regulation of airway inflammation and
hyper-responsiveness in asthma by mediating HMGB1 expression and
secretion. Exp Cell Res. 366:1–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Barrera-Avalos C, Briceño P, Valdés D,
Imarai M, Leiva-Salcedo E, Rojo LE, Milla LA, Huidobro-Toro JP,
Robles-Planells C, Escobar A, et al: P2X7 receptor is essential for
cross-dressing of bone marrow-derived dendritic cells. iScience.
24:1035202021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Romagnani A, Rottoli E, Mazza EMC,
Rezzonico-Jost T, De Ponte Conti B, Proietti M, Perotti M,
Civanelli E, Perruzza L, Catapano AL, et al: P2X7 receptor activity
limits accumulation of T cells within tumors. Cancer Res.
80:3906–3919. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Grassi F: The P2X7 receptor as regulator
of T cell development and function. Front Immunol. 11:11792020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xu C, Obers A, Qin M, Brandli A, Wong J,
Huang X, Clatch A, Fayed A, Starkey G, D'Costa R, et al: Selective
regulation of IFN-γ and IL-4 co-producing unconventional T cells by
purinergic signaling. J Exp Med. 221:e202403542024. View Article : Google Scholar
|
|
67
|
Brock VJ, Lory NC, Möckl F, Birus M,
Stähler T, Woelk LM, Jaeckstein M, Heeren J, Koch-Nolte F, Rissiek
B, et al: Time-resolved role of P2X4 and P2X7 during CD8+ T cell
activation. Front Immunol. 15:12581192024. View Article : Google Scholar
|
|
68
|
Knaus HA, Berglund S, Hackl H, Blackford
AL, Zeidner JF, Montiel-Esparza R, Mukhopadhyay R, Vanura K, Blazar
BR, Karp JE, et al: Signatures of CD8+ T cell dysfunction in AML
patients and their reversibility with response to chemotherapy. JCI
Insight. 3:e1209742018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Desai PN, Wang B, Fonseca A, Borges P,
Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, et al:
Single-cell profiling of CD8+ T cells in acute myeloid leukemia
reveals a continuous spectrum of differentiation and clonal
hyperexpansion. Cancer Immunol Res. CIR-22-09612023.PubMed/NCBI
|
|
70
|
Li Z, Philip M and Ferrell PB: Alterations
of T-cell-mediated immunity in acute myeloid leukemia. Oncogene.
39:3611–3619. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Pegoraro A and Adinolfi E: The ATP/P2X7
axis is a crucial regulator of leukemic initiating cells
proliferation and homing and an emerging therapeutic target in
acute myeloid leukemia. Purinergic Signal. 17:319–321. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G,
Rao Q, Nie K and Wu KF: Expression of P2X7 in human hematopoietic
cell lines and leukemia patients. Leuk Res. 28:1313–1322. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chong JH, Zheng GG, Zhu XF, Guo Y, Wang L,
Ma CH, Liu SY, Xu LL, Lin YM and Wu KF: Abnormal expression of P2X
family receptors in Chinese pediatric acute leukemias. Biochem
Biophys Res Commun. 391:498–504. 2010. View Article : Google Scholar
|
|
74
|
Salvestrini V, Orecchioni S, Talarico G,
Reggiani F, Mazzetti C, Bertolini F, Orioli E, Adinolfi E, Di
Virgilio F, Pezzi A, et al: Extracellular ATP induces apoptosis
through P2X7R activation in acute myeloid leukemia cells but not in
normal hematopoietic stem cells. Oncotarget. 8:5895–5908. 2017.
View Article : Google Scholar :
|
|
75
|
Ledderose C, Woehrle T, Ledderose S,
Strasser K, Seist R, Bao Y, Zhang J and Junger WG: Cutting off the
power: Inhibition of leukemia cell growth by pausing basal ATP
release and P2X receptor signaling? Purinergic Signal. 12:439–451.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mucha PT, Brahmachari A, Frańczak MA,
Tomczyk M, Kutryb-Zając B, Koszałka P, Giovannetti E and Peters GJ:
The role of the ecto-nucleotidases CD73 and CD39 in chemo- and
immunotherapy. Cancers (Basel). 18:9572026. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Feng L, Zhang H, Mao C, De Andrade Mello
P, Stroopinsky D, Csizmadia E, Zhou J, Avigan D, Yu J, Gao W and
Robson SC: Cd39 and P2rx7-wnt signaling enhance blast pathogenicity
in an experimental model of acute myeloid leukemia. Haematologica.
110:212–217. 2024.PubMed/NCBI
|
|
78
|
De Marchi E, Orioli E, Pegoraro A,
Sangaletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F and
Adinolfi E: The P2X7 receptor modulates immune cells infiltration,
ectonucleotidases expression and extracellular ATP levels in the
tumor microenvironment. Oncogene. 38:3636–3650. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Greve AS, Skals M, Fagerberg SK, Tonnus W,
Ellermann-Eriksen S, Evans RJ, Linkermann A and Praetorius HA:
P2X1, P2X4, and P2X7 receptor knock out mice expose differential
outcome of sepsis induced by α-haemolysin producing escherichia
coli. FronT cell Infect Microbiol. 7:1132017. View Article : Google Scholar
|
|
80
|
Bin Dayel A, Evans RJ and Schmid R:
Mapping the site of action of human P2X7 receptor antagonists
AZ11645373, brilliant blue G, KN-62, calmidazolium, and
ZINC58368839 to the intersubunit allosteric pocket. Mol Pharmacol.
96:355–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Filippin KJ, De Souza KFS, De Araujo
Júnior RT, Torquato HFV, Dias DA, Parisotto EB, Ferreira AT and
Paredes-Gamero EJ: Involvement of P2 receptors in hematopoiesis and
hematopoietic disorders, and as pharmacological targets. Purinergic
Signal. 16:1–15. 2020. View Article : Google Scholar :
|
|
82
|
Drill M, Jones NC, Hunn M, O'Brien TJ and
Monif M: Antagonism of the ATP-gated P2X7 receptor: A potential
therapeutic strategy for cancer. Purinergic Signal. 17:215–227.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Monaco S, Browne J, Wallace M, Angulo J
and Stokes L: On-cell saturation transfer difference NMR
spectroscopy on ion channels: Characterizing negative allosteric
modulator binding interactions of P2X7. J Am Chem Soc.
147:32400–32411. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
De Marchi E, Pegoraro A and Adinolfi E:
P2X7 receptor in hematological malignancies. FronT cell Dev Biol.
9:6456052021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Honore P, Donnelly-Roberts D, Namovic MT,
Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM,
Chandran P, et al: A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)
methyl]amino}-2,2-dimethylpropyl)-2-(3,4
-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor
antagonist, dose-dependently reduces neuropathic pain in the rat. J
Pharmacol Exp Ther. 319:1376–1385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Anderson CM and Nedergaard M: Emerging
challenges of assigning P2X7 receptor function and immunoreactivity
in neurons. Trends Neurosci. 29:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wang W, Xiao J, Adachi M, Liu Z and Zhou
J: 4-aminopyridine induces apoptosis of human acute myeloid
leukemia cells via increasing [Ca2+]i through P2X7
receptor pathway. Cell Physiol Biochem. 28:199–208. 2011.
View Article : Google Scholar
|
|
88
|
Rybalchenko V, Prevarskaya N, Van
Coppenolle F, Legrand G, Lemonnier L, Le Bourhis X and Skryma R:
Verapamil inhibits proliferation of LNCaP human prostate cancer
cells influencing K+ channel gating. Mol Pharmacol. 59:1376–1387.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cuthbertson P, Button A, Sligar C, Elhage
A, Vine KL, Watson D and Sluyter R: Post-transplant
cyclophosphamide combined with brilliant blue G reduces
graft-versus-host disease without compromising
graft-versus-leukaemia immunity in humanised mice. Int J Mol Sci.
25:17752024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Adinolfi E, Cirillo M, Woltersdorf R,
Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandonà D,
Markwardt F, Schmalzing G and Di Virgilio F: Trophic activity of a
naturally occurring truncated isoform of the P2X7 receptor. FASEB
J. 24:3393–3404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Pérez-Flores G, Lévesque SA, Pacheco J,
Vaca L, Lacroix S, Pérez-Cornejo P and Arreola J: The P2X7/P2X4
interaction shapes the purinergic response in murine macrophages.
Biochem Biophys Res Commun. 467:484–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zuanon M, Brancale A and Young MT:
Identification of new human P2X7 antagonists using ligand- and
structure-based virtual screening. J Chem Inf Model. 65:7143–7155.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Oken AC, Turcu AL, Tzortzini E, Georgiou
K, Nagel J, Westermann FG, Barniol-Xicota M, Seidler J, Kim GR, Lee
SD, et al: A polycyclic scaffold identified by structure-based drug
design effectively inhibits the human P2X7 receptor. Nat Commun.
16:82832025. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhang WJ, Luo HL, Liu JP, Xu YS, Wang WL
and Huang C: P2X7 receptor promotes the growth and metastasis of
gastric cancer by activating P13/AKT/GSK-3 beta signaling
(experimental research). Int J Surg Lond Engl. 111:3752–3766. 2025.
View Article : Google Scholar
|
|
95
|
Zhang WJ, Luo C, Huang C, Pu FQ, Zhu JF
and Zhu ZM: PI3K/akt/GSK-3β signal pathway is involved in P2X7
receptor-induced proliferation and EMT of colorectal cancer cells.
Eur J Pharmacol. 899:1740412021. View Article : Google Scholar
|
|
96
|
Zhang WJ, Hu CG, Luo HL and Zhu ZM:
Activation of P2×7 receptor promotes the invasion and migration of
colon cancer cells via the STAT3 signaling. FronT cell Dev Biol.
8:5865552020. View Article : Google Scholar
|
|
97
|
Keystone EC, Wang MM, Layton M, Hollis S
and McInnes IB; D1520C00001 Study Team: Clinical evaluation of the
efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the
signs and symptoms of rheumatoid arthritis in patients with active
disease despite treatment with methotrexate or sulphasalazine. Ann
Rheum Dis. 71:1630–1635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Eser A, Colombel J-F, Rutgeerts P,
Vermeire S, Vogelsang H, Braddock M, Persson T and Reinisch W:
Safety and efficacy of an oral inhibitor of the purinergic receptor
P2X7 in adult patients with moderately to severely active Crohn's
disease: A randomized placebo-controlled, double-blind, phase IIa
study. Inflamm Bowel Dis. 21:2247–2253. 2015.PubMed/NCBI
|
|
99
|
Danquah W, Meyer-Schwesinger C, Rissiek B,
Pinto C, Serracant-Prat A, Amadi M, Iacenda D, Knop JH, Hammel A,
Bergmann P, et al: Nanobodies that block gating of the P2X7 ion
channel ameliorate inflammation. Sci Transl Med. 8:366ra1622016.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Koch-Nolte F, Eichhoff A, Pinto-Espinoza
C, Schwarz N, Schäfer T, Menzel S, Haag F, Demeules M, Gondé H and
Adriouch S: Novel biologics targeting the P2X7 ion channel. Curr
Opin Pharmacol. 47:110–118. 2019. View Article : Google Scholar : PubMed/NCBI
|
